Saturday 17 October 2026
Export DNTH’s income statement to Excel — free account
Dianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024. In the quarter to June 2026, revenue grew 294.3%, EPS fell 2.27% and free cash flow fell 105.4%, each against the same quarter a year earlier.
72.09
2.44
−3.27%
Follow DNTH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
483.17 | 781.65 | 3,017.14 | 2,868.55 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(48.67) | (33.87) | (139.69) | (111.51) | |
P/B ratio |
2.72 | 3.23 | 3.36 | 4.66 | |
Price to Tangible BV |
2.72 | 3.23 | 3.36 | 4.66 | |
EV/Sales |
352.37 | 583.07 | 2,185.36 | 2,402.79 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.90) | (9.20) | (22.41) | (29.44) | |
EV/FCF |
(9.89) | (9.18) | (22.38) | (29.38) | |
Quick Ratio |
17.09 | 13.16 | 29.06 | 25.79 | |
Current Ratio |
17.35 | 13.32 | 29.25 | 26.10 | |
Net Debt/EBITDA |
9.47 | 5.75 | 23.31 | 13.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.83 | 0.73 | 0.71 | 0.98 | |
Capex/Depreciation |
0.00 | 0.18 | 0.01 | 0.03 | |
Research and Development Expense of Revenue |
8,204.29% | 21,089.79% | 7,457.45% | 6,397.63% | |
Selling, General and Administrative Expense of Revenue |
2,069.44% | 3,496.48% | 2,692.87% | 1,781.47% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,463.13% | 2,104.93% | 2,289.85% | 1,563.47% | |
Graham Net Nets |
0.26 | 0.23 | 0.27 | 0.16 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.84%) | (9.95%) | (4.92%) | (4.26%) | |
Free Cash Flow Yield |
(7.37%) | (8.12%) | (3.24%) | (2.85%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.81) | (1.22) | (0.60) | (0.87) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.81) | (1.22) | (0.60) | (0.88) | |
Cash per Share |
10.65 | 10.47 | 23.14 | 15.83 | |
Shareholders Equity per Share |
14.46 | 12.78 | 25.01 | 20.92 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.46 | 12.78 | 25.01 | 20.92 | |
Free Cash Flow |
(30.56) | (47.12) | (28.87) | (49.16) | |
Working Capital |
389.97 | 378.71 | 1,081.63 | 863.15 | |
Capital Expenditures |
0.00 | (0.14) | (0.01) | (0.18) | |
Net Current Asset Value |
382.83 | 371.92 | 1,074.34 | 856.29 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.49 | 0.02 | 0.24 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.84 | 0.43 | 1.12 | 0.07 | |
Average Payables |
7.14 | 7.15 | 6.77 | 5.90 | |
Average Assets |
465.85 | 452.47 | 797.73 | 769.67 | |
Average Common Equity |
442.18 | 422.94 | 764.96 | 737.55 |
Columns are period end dates